Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system

Rasmus F Brøndum; Anne S Vestergaard; Lars Børty; Charles Vesteghem; Anne S Rytter; Marlene M Nielsen; Marianne T Severinsen; Paw Jensen; Henrik Gregersen; Tarec C El-Galaly; Karen Dybkær; Lars H Ehlers; Martin Bøgsted; Anne S Roug

doi:10.2217/fon-2021-0189

Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system

Rasmus F Brøndum^*, Anne S Vestergaard, Lars Børty, Charles Vesteghem, Anne S Rytter, Marlene M Nielsen, Marianne T Severinsen, Paw Jensen, Henrik Gregersen, Tarec C El-Galaly, Karen Dybkær, Lars H Ehlers, Martin Bøgsted, Anne S Roug

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Aim: To estimate current real-world costs of drugs and supportive care for the treatment of multiple myeloma in a tax-based health system. Methods: Forty-one patients were included from a personalized medicine study (2016-2019). Detailed information was collected from patient journals and hospital registries to estimate the total and mean costs using inverse probability weighting of censored data. Results: Total observed (censored) costs for the 41 patients was €8.84 million during 125 treatment years, with antineoplastic drugs as the main cost driver (€5.6 million). Individual costs showed large variations. Mean 3-year cost per patient from first progression was €182,103 (€131,800-232,405). Conclusion: Prediction of real-world costs is hindered by the availability of detailed costing data. Micro-costing analyses are needed for budgeting and real-world evaluation of cost-effectiveness.

Original language	English
Journal	Future Oncology
Volume	17
Issue number	25
Pages (from-to)	3331-3341
Number of pages	11
ISSN	1479-6694
DOIs	https://doi.org/10.2217/fon-2021-0189
Publication status	Published - Sept 2021

Keywords

antineoplastic agents
healthcare costs
micro-costing
multiple myeloma
supportive care

Access to Document

10.2217/fon-2021-0189

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Brøndum, R. F., Vestergaard, A. S., Børty, L., Vesteghem, C., Rytter, A. S., Nielsen, M. M., Severinsen, M. T., Jensen, P., Gregersen, H., El-Galaly, T. C., Dybkær, K., Ehlers, L. H., Bøgsted, M., & Roug, A. S. (2021). Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system. Future Oncology, 17(25), 3331-3341. https://doi.org/10.2217/fon-2021-0189

@article{6c75b8f6ef1c42b09e68801b42ae9fa0,

title = "Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system",

abstract = "Aim: To estimate current real-world costs of drugs and supportive care for the treatment of multiple myeloma in a tax-based health system. Methods: Forty-one patients were included from a personalized medicine study (2016-2019). Detailed information was collected from patient journals and hospital registries to estimate the total and mean costs using inverse probability weighting of censored data. Results: Total observed (censored) costs for the 41 patients was €8.84 million during 125 treatment years, with antineoplastic drugs as the main cost driver (€5.6 million). Individual costs showed large variations. Mean 3-year cost per patient from first progression was €182,103 (€131,800-232,405). Conclusion: Prediction of real-world costs is hindered by the availability of detailed costing data. Micro-costing analyses are needed for budgeting and real-world evaluation of cost-effectiveness.",

keywords = "antineoplastic agents, healthcare costs, micro-costing, multiple myeloma, supportive care",

author = "Br{\o}ndum, {Rasmus F} and Vestergaard, {Anne S} and Lars B{\o}rty and Charles Vesteghem and Rytter, {Anne S} and Nielsen, {Marlene M} and Severinsen, {Marianne T} and Paw Jensen and Henrik Gregersen and El-Galaly, {Tarec C} and Karen Dybk{\ae}r and Ehlers, {Lars H} and Martin B{\o}gsted and Roug, {Anne S}",

year = "2021",

month = sep,

doi = "10.2217/fon-2021-0189",

language = "English",

volume = "17",

pages = "3331--3341",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "25",

}

Brøndum, RF, Vestergaard, AS, Børty, L , Vesteghem, C, Rytter, AS, Nielsen, MM, Severinsen, MT , Jensen, P , Gregersen, H , El-Galaly, TC , Dybkær, K, Ehlers, LH, Bøgsted, M & Roug, AS 2021, 'Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system', Future Oncology, vol. 17, no. 25, pp. 3331-3341. https://doi.org/10.2217/fon-2021-0189

TY - JOUR

T1 - Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system

AU - Brøndum, Rasmus F

AU - Vestergaard, Anne S

AU - Børty, Lars

AU - Vesteghem, Charles

AU - Rytter, Anne S

AU - Nielsen, Marlene M

AU - Severinsen, Marianne T

AU - Jensen, Paw

AU - Gregersen, Henrik

AU - El-Galaly, Tarec C

AU - Dybkær, Karen

AU - Ehlers, Lars H

AU - Bøgsted, Martin

AU - Roug, Anne S

PY - 2021/9

Y1 - 2021/9

N2 - Aim: To estimate current real-world costs of drugs and supportive care for the treatment of multiple myeloma in a tax-based health system. Methods: Forty-one patients were included from a personalized medicine study (2016-2019). Detailed information was collected from patient journals and hospital registries to estimate the total and mean costs using inverse probability weighting of censored data. Results: Total observed (censored) costs for the 41 patients was €8.84 million during 125 treatment years, with antineoplastic drugs as the main cost driver (€5.6 million). Individual costs showed large variations. Mean 3-year cost per patient from first progression was €182,103 (€131,800-232,405). Conclusion: Prediction of real-world costs is hindered by the availability of detailed costing data. Micro-costing analyses are needed for budgeting and real-world evaluation of cost-effectiveness.

AB - Aim: To estimate current real-world costs of drugs and supportive care for the treatment of multiple myeloma in a tax-based health system. Methods: Forty-one patients were included from a personalized medicine study (2016-2019). Detailed information was collected from patient journals and hospital registries to estimate the total and mean costs using inverse probability weighting of censored data. Results: Total observed (censored) costs for the 41 patients was €8.84 million during 125 treatment years, with antineoplastic drugs as the main cost driver (€5.6 million). Individual costs showed large variations. Mean 3-year cost per patient from first progression was €182,103 (€131,800-232,405). Conclusion: Prediction of real-world costs is hindered by the availability of detailed costing data. Micro-costing analyses are needed for budgeting and real-world evaluation of cost-effectiveness.

KW - antineoplastic agents

KW - healthcare costs

KW - micro-costing

KW - multiple myeloma

KW - supportive care

UR - http://www.scopus.com/inward/record.url?scp=85113357835&partnerID=8YFLogxK

U2 - 10.2217/fon-2021-0189

DO - 10.2217/fon-2021-0189

M3 - Journal article

C2 - 34156281

SN - 1479-6694

VL - 17

SP - 3331

EP - 3341

JO - Future Oncology

JF - Future Oncology

IS - 25

ER -

Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system

Abstract

Keywords

Access to Document

AUB Link

Other files and links

Fingerprint

Supplementary Table_S1: Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system.xlsx

Cite this

Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system

Abstract

Keywords

Access to Document

AUB Link

Other files and links

Fingerprint

Datasets

Supplementary Table_S1: Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system.xlsx

Cite this